NYSE:RCUS

Arcus Biosciences Stock Insider Trading

etoro logo Buy RCUS
*Your capital is at risk
$28.19
-0.0600 (-0.212%)
At Close: Jul 31, 2026

Arcus Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -68.07. In total, the insiders bought 1.79M and sold 739.53K RCUS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-68.07
Buy 1.79M shares
Sell 739.53K shares
48% Buy Activity
Moderate Negative Correlation
Sell Signal High Confidence
Jul 10, 2026

Analysis Breakdown:

  • Strongly supported by a very low Insider Power Score of -68.07.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jul 10, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 268
Value: $8K
Jul 10, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 19 799
Value: $566.4K
Jul 09, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 48 502
Value: $1.46M
Jun 24, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 6 431
Value: $190.7K
Jun 23, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 1 697
Value: $47.6K
Jun 23, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 14 067
Value: $389.5K
Jun 22, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 9 236
Value: $249.7K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Perlman Andrew J
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
A-Award
Perlman Andrew J
Director
Director 5 700
Value: $132.8K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Ribas Antoni
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
A-Award
Ribas Antoni
Director
Director 5 700
Value: $132.8K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Falberg Kathryn E
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
A-Award
Lambert Nicole
Director
Director 5 700
Value: $132.8K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Lambert Nicole
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
A-Award
Machado Patrick
Director
Director 5 700
Value: $132.8K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Machado Patrick
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
A-Award
Kaneko Yasunori
Director
Director 5 700
Value: $132.8K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Kaneko Yasunori
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
M-Exempt
Tang Carolyn C.
General Counsel
Officer 34 090
Value: $87.7K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Tang Carolyn C.
General Counsel
Officer 34 090
Value: $87.7K
Jun 11, 2026
Buy
Common Stock
A-Award
Lacey David L.
Director
Director 5 700
Value: $132.8K
Jun 11, 2026
Buy
Stock Option (Right to Buy)
A-Award
Lacey David L.
Director
Director 16 900
Value: $393.8K
Jun 11, 2026
Buy
Common Stock
A-Award
Falberg Kathryn E
Director
Director 5 700
Value: $132.8K
Jun 01, 2026
Sell
Common Stock
S-Sale
Azoy Alexander
Chief Accounting Officer
Officer 2 562
Value: $66.0K
May 11, 2026
Sell
Common Stock
S-Sale
Goeltz Ii Robert C.
Chief Financial Officer
C-Suite Officer 7 763
Value: $199.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ARCUS BIOSCIENCES INC.
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE